Filing Details

Accession Number:
0001127602-24-005355
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-16 16:10:40
Reporting Period:
2024-02-14
Accepted Time:
2024-02-16 16:10:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1443340 Stephane Bancel C/O Moderna, Inc.
200 Technology Square
Cambridge MA 02139
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-14 56,736 $0.00 5,486,575 No 4 A Direct
Common Stock Disposition 2024-02-16 26,351 $88.88 5,460,224 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,050,372 Indirect See Footnote
Common Stock 6,564,880 Indirect See Footnote
Footnotes
  1. These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
  2. These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
  3. The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 5, 2021 (the "2021 PSUs").
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the 2021 PSUs. This "sell-to-cover" transaction was mandated by the Issuer's equityincentive plan and does not represent a discretionary trade by the reporting person.